In a recent study, Novo Nordisk's next-generation basal insulin degludec was found to cause less hypoglycemia than Lantus. In early May, Novo Nordisk announced the...
Diabetes Drug News
Diabetes Drugs are responsible for helping to decrease blood sugar levels so that you can try to stay in a healthier range and help avoid serious complications.
Metformin Insulin SGLT-2 GLP-1 DPP-4 Combo drugs Sulfonylureas TZDs
34 readers recommended
Novo Nordisk continues to make headway in the development of Degludec and DegludecPlus, the company’s two new “next-generation” insulins. The company recently announced...
59 readers recommended
In early November, Kombiglyze, a pill combining DPP-4 inhibitor Onglyza and metformin, was approved by the FDA for type 2 diabetes. Onglyza was approved in July 2010...
44 readers recommended
In mid-April, the European Medicine Agency's Committee for Medicinal Products for Human Use (a committee called the "CHMP") recommended that Amylin/Lilly/Alkermes' once-...
39 readers recommended
The FDA’s decision on Bydureon was a shocker. We break down this decision and discuss why we view it as such a disappointment.
45 readers recommended
In late 2010, Merck announced that it had acquired SmartCells, a small Massachusetts-based company that is developing a smart insulin product aptly named SmartInsulin...
41 readers recommended
People with diabetes are at significantly increased risk for kidney impairment or kidney failure. Kidney disease can complicate the treatment of type 2 diabetes because...
47 readers recommended
Type 1s and GLP-1s? diaTribe Editor-In-Chief Kelly Close tries Victoza and shares her remarkable results.
65 readers recommended
Earlier this month, Eli Lilly and the German pharmaceutical Boehringer Ingelheim (BI) announced a major partnership to co-develop and co-commercialize several of their...
48 readers recommended
Can Victoza help people with type 1 diabetes? See what Novo Nordisk has to say inside.
36 readers recommended
In a major setback for MannKind Corporation ’s inhalable insulin therapy, Afrezza, the FDA is requiring the company to conduct two additional clinical trials of the...
31 readers recommended
Novo Nordisk’s “next-generation” basal insulin degludec. Novo Nordisk has released promising data from a 7,000-participant clinical trial for its next-generation basal...
27 readers recommended
Just in time for the New Year, Kelly reveals good news on obesity therapies and insulin delivery devices.
46 readers recommended
Novo Nordisk’s once daily GLP-1 agonist Victoza (above) provided slightly better improvements in blood glucose control than Amylin/Eli Lilly/ Alkermes’s once weekly GLP-...
39 readers recommended
A thorough review and “how-to” on the drug Symlin (Amylin’s pramlintide).
38 readers recommended
Last week, in a surprise and, in our view, disappointing move, the FDA decided to not approve Bydureon, a once-weekly GLP-1 agonist, for use in the United States despite...
45 readers recommended
For type 2 patients, the use of GLP-1 agonists (such as Victoza and Byetta ) can often lead to significant improvements in blood glucose control and weight loss with...
28 readers recommended
A girl can dream, right? (...of cures and new insulins...)
47 readers recommended
On January 27, the Food and Drug Administration (FDA) granted approval to Bydureon, a new drug for type 2 diabetes that is injected once a week. Approved last year in...
22 readers recommended
Kelly’s take on the maddeningly slow FDA approval process and why things are probably getting better.